Affibody has obtained a granted patent on the Microbead display technology
Affibody AB announced that the European patent office has granted a patent application regarding a Microbead-based system to be used for rapid selection of Affibody® molecules and other small binding proteins. Last year the US patent office granted the Company a patent on this principle.
In contrast to selection principles based on biological systems, such as phage display, the Microbead display technology is a cell free system without the limiting factors associated with transformation of DNA into cells, enabling the creation of larger libraries. According to the company, a further advantage is that all steps in the Microbead selection technology are performed in vitro, i.e. in the test tube, enabling automization of all unit operations. The US and EU patents are the first to be granted on this principle and derives from the first filed patents on a bead-based selection system.
Other news from the department research and development
